Short answer
Biomarin Pharmaceutical Inc (BMRN) filed an 8-K current report with the SEC on August 6, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Q2 2026 financial results announced for quarter ended June 30, 2026.
Biomarin Pharmaceutical Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Q2 2026 financial results announced for quarter ended June 30, 2026
- Full operating metrics and management commentary available in Exhibit 99.1 press release
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $990M, up 20% year over year, led by Amicus products GALAFOLD and POMBILITI + OPFOLDA plus VOXZOGO growth
- GAAP net income fell 81% to $45M, reflecting Amicus integration costs, amortization, financing interest and inventory step-up charges
- 2026 revenue guidance raised to $3.875B-$3.925B, while VOXZOGO guidance increased to $1.0B-$1.05B
- Non-GAAP diluted EPS guidance raised to $4.90-$5.10, despite approximately $200M annualized Amicus financing interest expense
- Amicus integration targets approximately $220M non-GAAP cost synergies by 2028, with gross leverage below 2.5 times targeted by mid-2027
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Biomarin Pharmaceutical Inc 8-K filings
Get the next BMRN 8-K as it lands
Follow BMRN for push alerts, or ask the research agent what this filing means.